Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Science · 02.02.2024 · 383 (6682)
DOI: 10.1126/science.adi5798 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 02.02.2024. Verfasst von Skye Montoya und 52 weiteren Autor:innen. Beteiligte Einrichtung: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Ikaros Transcription Factor, Leukemia, Lymphocytic, Chronic, B-Cell, Protein Kinase Inhibitors. Die Arbeit wurde bisher 185-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Increasing use of covalent and noncovalent inhibitors of Bruton’s tyrosine kinase (BTK) has elucidated a series of acquired drug-resistant BTK mutations in patients with B cell malignancies. Here we identify inhibitor resistance mutations in BTK with distinct enzymatic activities, including some that impair BTK enzymatic activity while imparting novel protein-protein interactions that sustain B cell receptor (BCR) signaling. Furthermore, we describe a clinical-stage BTK and IKZF1/3 degrader, NX-2127, that can bind and proteasomally degrade each mutant BTK proteoform, resulting in potent blockade of BCR signaling. Treatment of chronic lymphocytic leukemia with NX-2127 achieves >80% degradation of BTK in patients and demonstrates proof-of-concept therapeutic benefit. These data reveal an oncogenic scaffold function of mutant BTK that confers resistance across clinically approved BTK inhibitors but is overcome by BTK degradation in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
- Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Nurix Therapeutics, San Francisco, CA, USA.
- Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
- K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
ORCID-Profile: Skye Montoya, Jessie Bourcier, Mark Noviski, Meghan C Thompson, Alexandra Chirino, Jacob Jahn, Anya K Sondhi, Stefan Gajewski, Ying Siow May Tan, Aleksandra Urban, Cuijuan Han, Xiaoli Mi, Won Jun Kim, Quinlan Sievers, Paul Auger, James N Iuliano, Tim Kane, Ratul Mukerji, Panga Jaipal Reddy, Jordan Ye, Carla Barrientos Risso, Daniel Tsai, Ryan Q Notti, Maurizio Affer, Tulasigeri M Totiger, Joanna M Rhodes, Andrew D Zelenetz, Lindsey E Roeker, Sanjoy Mehta, Adam Linley, Rajesh Kumar Soni, Sigrid S Skånland, Robert J Brown, Gwenn M Hansen, Omar Abdel-Wahab, Justin Taylor
Förderung
- NCI NIH HHS
- NIH HHS
- NHLBI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Montoya, S., Bourcier, J., Noviski, M., Lu, H., Thompson, M. C., Chirino, A., Jahn, J., Sondhi, A. K., Gajewski, S., Tan, Y. S. M., Yung, S., Urban, A., Wang, E., Han, C., Mi, X., Kim, W. J., Sievers, Q., Auger, P., Bousquet, H., …, & Taylor, J. (2024). Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science, 383(6682). https://doi.org/10.1126/science.adi5798
Vancouver
Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, et al. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science. 2024;383(6682). doi:10.1126/science.adi5798
BibTeX
@article{Montoya2024,
author = {Montoya, Skye and Bourcier, Jessie and Noviski, Mark and Lu, Hao and Thompson, Meghan C and Chirino, Alexandra and Jahn, Jacob and Sondhi, Anya K and Gajewski, Stefan and Tan, Ying Siow May and Yung, Stephanie and Urban, Aleksandra and Wang, Eric and Han, Cuijuan and Mi, Xiaoli and Kim, Won Jun and Sievers, Quinlan and Auger, Paul and Bousquet, Hugo and Brathaban, Nivetha and Bravo, Brandon and Gessner, Melissa and Guiducci, Cristiana and Iuliano, James N and Kane, Tim and Mukerji, Ratul and Reddy, Panga Jaipal and Powers, Janine and Sanchez Garcia de Los Rios, Mateo and Ye, Jordan and Barrientos Risso, Carla and Tsai, Daniel and Pardo, Gabriel and Notti, Ryan Q and Pardo, Alejandro and Affer, Maurizio and Nawaratne, Vindhya and Totiger, Tulasigeri M and Pena-Velasquez, Camila and Rhodes, Joanna M and Zelenetz, Andrew D and Alencar, Alvaro and Roeker, Lindsey E and Mehta, Sanjoy and Garippa, Ralph and Linley, Adam and Soni, Rajesh Kumar and Skånland, Sigrid S and Brown, Robert J and Mato, Anthony R and Hansen, Gwenn M and Abdel-Wahab, Omar and Taylor, Justin},
title = {Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127},
journal = {Science},
year = {2024},
volume = {383},
number = {6682},
doi = {10.1126/science.adi5798}
}
EUVIMED